MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerat

Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular se

Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular ses

Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-

Generac shares jumped 34.8% after an up-to-$8B Amazon data-center generator deal; other premarket mo

Longeveron shares fell 59% after hours after its ELPIS II trial missed its primary endpoint.

Longeveron on Wednesday said it would explore strategic options after its experimental stem cell the

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement

Company Announces Exploration of All Options to Maximize Shareholder Value The top line results show

Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place S

U.S. stock futures advanced on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, f

US stock futures mixed as investors focus on earnings from Dick's Sporting Goods, Trade Desk, In

Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy fo

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnol

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy fo

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business developm

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's aft

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst con

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laro

Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonst

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage rege

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnolo

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy fo

Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) entitled “La

Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for

Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech s

Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript

Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's

Poster Presentation (Exhibit Hall) Date:Monday, July 13, 2026Time:7:30am – 4:15pm BSTSession:In-Pers

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnol

According to the EMA, SME Designation has allowed for improved success rate for organizations seekin

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnol

https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.h

Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportu

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnolo

Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst con

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromes

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLH

The Company intends to submit to the FDA a Sponsor Statistical Analysis Plan (SAP) for ELPIS II with

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy

https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026042461/ea0285827-s1_longeveron.h

https://scr.zacks.com/files/News/2026/Zacks_SCR_Research_03182026_LGVN_Sorensen.pdf